LONG MINI-FUTURE - GENMAB | Real-time Boerse Frankfurt Warrants 01:53:37 2024-07-10 pm EDT | ||
| 1.73 EUR | -6.49% |
|
| Current month | +9.49% | ||
| 1 month | -56.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 1.73 | -6.49% |
| 24-07-09 | 1.85 | +14.20% |
| 24-07-08 | 1.62 | -2.41% |
| 24-07-05 | 1.66 | +17.73% |
| 24-07-04 | 1.41 | -2.76% |
Real-time Boerse Frankfurt Warrants
Last update July 10, 2024 at 01:53 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP2AVZ |
| ISIN | DE000VP2AVZ4 |
| Date issued | 2020-04-06 |
| Strike | 1,628 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.85 € |
|---|---|
| Lowest since issue | 1.1 € |
| Spread | 0.02 € |
| Spread % | 0.99% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,765
DKK
Average target price
2,446
DKK
Spread / Average Target
+38.60%
- Stock Market
- Certificates
- Certificat
